<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528983</url>
  </required_header>
  <id_info>
    <org_study_id>AZA PH US 2007 CL005</org_study_id>
    <nct_id>NCT00528983</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia</brief_title>
  <official_title>A Phase 1, Open-label, Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a tablet form of azacitidine that taken by
      mouth is safe. This Phase I study will also look at different doses and different treatment
      schedules in order to better understand the effects (positive and negative) of oral
      azacitidine on the body and on the disease MDS, AML and CMML.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optional Extension Phase (OEP) to the AZA PH US 2007 CL 005 study which allows subjects who
      continue to receive oral azacitidine and have stable disease or are demonstrating clinical
      benefit as assessed by the Investigator, and have consented to participate, may enter the OEP
      of this study (at their current doses) at the start of their next cycle.

      Subjects who are entering the OEP should be discontinued from Part 1 or Part 2 protocol
      prescribed therapy in the AZA PH US 2007 CL 005 study.

      Subjects may continue to receive oral azacitidine in the OEP until they meet the criteria for
      study discontinuation or oral azacitidine becomes commercially available. Subjects
      discontinuing from the OEP will have an OEP discontinuation visit 28 days after the last dose
      of study drug or at study withdrawal.

      Primary Objective of OEP is to evaluate long term safety of oral azacitidine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation as measured by monitoring AEs, dose limiting toxicities, scheduled lab assessments, vital sign measurements, ECGs, &amp; physical exams for study duration. Adverse changes in physical signs/symptoms will be graded according to CTC AE V.3.0.</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated dose</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic blood and bone marrow samples will be collected and evaluated.</measure>
    <time_frame>60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessed by evidence of response (MDS subjects) and/or hematologic improvement (MDS subjects) examined using IWG criteria.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biologically active dose based on safety, PK and PD data.</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Myelodysplastic Syndromes (MDS)</condition>
  <condition>Chronic Myelomonocytic Leukemia (CMML)</condition>
  <condition>Acute Myelogenous Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Subcutaneous (SC) Azacitidine and Oral Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous (SC) Azacitidine</intervention_name>
    <description>75 mg/day for first 7 days of 28 day cycle for 1 cycle only.</description>
    <arm_group_label>Subcutaneous (SC) Azacitidine and Oral Azacitidine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Azacitidine</intervention_name>
    <description>Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.</description>
    <arm_group_label>Subcutaneous (SC) Azacitidine and Oral Azacitidine</arm_group_label>
    <other_name>CC-486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Azacitidine</intervention_name>
    <description>Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.</description>
    <arm_group_label>Oral Azacitidine</arm_group_label>
    <other_name>CC-486</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older.

          -  Diagnosis of low or Int-1 risk MDS

          -  Low platelet count, and/or low hemoglobin, and/or RBC transfusion-dependent and/or
             platelet transfusion-dependent

          -  ECOG Performance status 0-2

          -  Standard safety inclusion for serum creatinine, AST, ALT, bilirubin.

          -  Serum bicarbonate greater than or equal to 20 mEq/L.

          -  Use of acceptable birth control.

          -  Signed, written informed consent.

        Exclusion Criteria:

          -  Diagnosis of acute PML.

          -  Previous or concurrent malignancy.

          -  Prior treatment with azacitidine or other demethylating agents.

          -  Treatment with any anticancer therapy or investigational drugs within 21 days.

          -  Hypersensitivity to azacitidine or mannitol.

          -  Presence of GI disease.

          -  Active, uncontrolled infection.

          -  Known Human Immunodeficiency Virus (HIV) or Hepatitis C, or known active viral
             Hepatitis B.

          -  Breastfeeding or Pregnant females;

          -  Presence of serious illness, medical condition, or other medical history which would
             be likely to interfere with a subject's participation in the study or with the
             interpretation of the results.

          -  Current congestive heart failure (NY Heart Association Class III-IV), unstable angina
             or angina requiring surgical or medical intervention within 6 months, myocardial
             infarct within 6 months, or uncontrolled cardiac arrhythmia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Skikne, M.D., FACP; FCP (SA)</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Translational Oncology Research IRB</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Care</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOAST</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-4417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/ North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011 Jun 20;29(18):2521-7. doi: 10.1200/JCO.2010.34.4226. Epub 2011 May 16.</citation>
    <PMID>21576646</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes MDS</keyword>
  <keyword>Acute Myelogenous Leukemia AML</keyword>
  <keyword>Chronic Myelomonocytic Leukemia CMML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

